Novo Nordisk A/S - share repurchase programme

Core Viewpoint - Novo Nordisk has initiated a share repurchase program of up to DKK 20 billion, starting from 6 February 2024, with a specific repurchase amount of DKK 2.2 billion from 7 May 2024 to 5 August 2024 [1][3]. Group 1: Share Repurchase Program Details - The share repurchase program is in accordance with the Safe Harbour Rules under European regulations [1]. - As of 16 May 2024, Novo Nordisk has repurchased a total of 8,976,250 B shares at an average price of DKK 862.94, amounting to a transaction value of DKK 7,745,929,232 since the program began [3]. - The total number of B shares repurchased from 7 May 2024 to 16 May 2024 is 242,000, with a cumulative transaction value of DKK 218,194,459 [2][3]. Group 2: Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923, headquartered in Denmark, and focuses on chronic diseases, particularly diabetes [4]. - The company employs approximately 66,000 people across 80 countries and markets its products in around 170 countries [4]. - Novo Nordisk's B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange [4].